Try a new search

Format these results:

Searched for:

school:LISOM

Total Results:

14957


Contemporary clinical characteristics, management strategies, and outcomes of fluoropyrimidine-induced angina - A descriptive study

Zalaquett, Ziad; Chedid El Helou, Michel; Laderian, Bahar; Shukla, Neehal; Griffin, Brian; Moudgil, Rohit; Collier, Patrick
Fluoropyrimidines can cause angina-like chest pain, often attributed to coronary vasospasm. We retrospectively reviewed 137 patients at Cleveland Clinic (2017-2023) who developed chest pain during 5-fluorouracil or capecitabine treatments. Most events occurred early (75 % within four cycles). Troponin elevation (42 %) and ischemic electrocardiographic changes (43 %) were common, yet most catheterized patients had no obstructive coronary disease. Rechallenge was attempted in 64 % of patients, with recurrence in 36 %, and no predictors of recurrence were identified. Fluoropyrimidine-associated angina is therefore frequent, with high rates of recurrence, and unpredictable, highlighting the need for standardized diagnostic and management strategies.
PMID: 41319731
ISSN: 1876-4738
CID: 6076228

Spontaneous Regression of Colon Adenocarcinoma: A Case for Reconsideration [Case Report]

Dehghani, S Sharareh; Kaul, Arunima; Hertan, Hilary; Laderian, Bahar; Andreade, Christopher
PMID: 41412912
ISSN: 1938-0674
CID: 6076227

NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study

Mohamed, A; Azmi, A; Kocak, M; Sonbol, M B; Konda, B; Dowlati, A; Nagel, C; Haider, M; Laderian, B; Asa, S L; Tirumani, S H; Garcia, J; Mahipal, A; Bajor, D; Chakrabarti, S; Selfridge, J E; Conces, M; Lumish, M; Hoehn, R S; Winter, J; Fu, P; Ammori, J; Hardacre, J; Henke, L E; Khan, H Y; Morgan, C; Raheem, D Abedal; Donohue, D; Fowler, P; Kaseb, A
Extrapulmonary neuroendocrine carcinomas (EP-NECs) are a heterogeneous group of rare tumors with poor clinical outcomes. These patients have limited treatment options after progressing on first-line platinum-based chemotherapy. Although dual immune checkpoint inhibitors (ICIs) with anti-CTLA-4 and anti-PD-1 blockade have significantly improved outcomes for several solid tumors, they demonstrated modest activity for EP-NECs with 9-26% response rates and low survival rates. Preliminary data demonstrated that NP-101 (Nigella sativa formulation) enhances T-cell infiltration and is synergistic with dual ICPIs in NECs' cellular models. This pilot study evaluated the tolerability and efficacy of NP-101 plus nivolumab and ipilimumab in patients with metastatic EP-NECs refractory to first-line platinum-based chemotherapy. This is a single-arm pilot study (NCTNCT05262556) in which patients with metastatic EP-NECs received NP-101 (oral capsules), 3,000 mg daily, plus ICPIs (intravenous nivolumab 3 mg/kg and ipilimumab 1 mg/kg) every 3 weeks for four cycles. Nonprogressors received NP-101 (3,000 mg daily), plus biweekly maintenance of nivolumab (240 mg), and then completed 24 weeks of treatment. Treatment-related adverse events (TR-AEs) were characterized according to CTCAE v4.03. The response rate was estimated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The Kaplan-Meir method was used to estimate median PFS and OS. Twelve patients received ≥1 dose of NP-101 and nivolumab plus ipilimumab. There were no dose-limiting toxicities (DLTs). Grade 1/2 TR-AEs occurred in 100% (12/12) of patients. The most common G1/2 TR-AEs included the following: fatigue (75%), nausea (41.7%), pruritus (41.7%), muscle weakness (33.3%), vomiting (25%), rash (25%), and abdominal pain (25%). Eight patients (66%) experienced grade 3/4 TR-AEs, including rash (33.3%), nausea (16.7%), vomiting (16.7%), and transaminitis (16.7%). No treatment-related grade 5 toxicities or deaths were recorded. The objective response rate was 41.7% (2/12 (16%) complete response (CR) + 3/12 (25%) partial response (PR); 95% CI: 15.2-72.3%) for all patients and 50% (2/8 CR + 2/8 PR, 95% CI: 0.16-0.84) for patients with NEC of gastrointestinal origin. The median duration of response was 7.5 months. As for the median progression-free survival, it was 5.7 months, and the median overall survival (OS) was 10.5 months with a median follow-up of 10.4 months. The combination of NP-101 plus dual ICPIs (nivolumab and ipilimumab) was safe and well tolerated with preliminary evidence of antineoplastic activity. Currently, a randomized phase II clinical trial evaluating the combination is under development.
PMID: 42012995
ISSN: 1479-6821
CID: 6076226

Corrigendum to Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations Transplant Cell Ther. 2025 Sep;31(9):680-692. doi: 10.1016/j.jtct.2025.05.019. Epub 2025 May 24

Mehta, Rohtesh S; Schmidt, Gabrielle; Williams, Kirsten; Patel, Shyam A; Schetelig, Johannes; Savani, Bipin; Askar, Medhat; Petersdorf, Effie; Ringden, Olle; Kanakry, Christopher G; Kanakry, Jennifer A; Stefanski, Heather; Arrieta-Bolaños, Esteban; Betts, Brian; Benjamin, Cara; Gadalla, Shahinaz; Wang, Tao; Saultz, Jennifer; Spellman, Stephen; Jurdi, Najla El; Bolon, Yung-Tsi; Lee, Stephanie J
PMID: 42956832
ISSN: 2666-6367
CID: 6076197

Safety and Efficacy of Low-Dose Ketamine Infusion for Pain Management after Cardiac Surgery:A Single Center Pre-Post Analysis

Hall, James; Yi, Hyogun; Weihs, Jenna; Rajan, Anand; Weinberger, Andrew; Sharma, Vivek; Yoo, Noah
OBJECTIVES/OBJECTIVE:To evaluate whether the addition of continuous low-dose ketamine infusion to an enhanced recovery after surgery (ERAS) protocol reduces postoperative opioid consumption and improves pain control after cardiac surgery. DESIGN/METHODS:Single-center, retrospective, before-and-after cohort study with propensity score matching. SETTING/METHODS:University-affiliated tertiary care hospital cardiothoracic intensive care unit. PARTICIPANTS/METHODS:Adult patients undergoing cardiac surgery and admitted postoperatively to the cardiothoracic intensive care unit between June 2023 and January 2025. INTERVENTIONS/METHODS:Patients managed under an ERAS protocol without ketamine (control) were compared with patients managed under ERAS plus a continuous postoperative low-dose ketamine infusion (0.1-0.3 mg/kg/h). MEASUREMENTS AND MAIN RESULTS/RESULTS:The primary outcome was opioid consumption in morphine milligram equivalents (MME) from postoperative day (POD) 0-2. Secondary outcomes included pain scores, time to first analgesic, recovery metrics, length of stay, and adverse events. Of 548 screened patients, 244 were included after propensity matching (122 ketamine, 122 control). Ketamine was associated with lower cumulative opioid use through POD2 (30 vs 52.5 MME; p = 0.003), with reductions on POD0 and POD1. Time to first analgesic was longer (7.4 vs 4.5 h; p < 0.001), and maximum pain scores were lower across the first 48 hours (all p < 0.05). Intensive care unit length of stay was modestly longer, while hospital length of stay was shorter in the ketamine group. No hallucinations were observed, delirium rates were low, and urinary retention was significantly reduced (9.8% vs 34%; p < 0.001). CONCLUSION/CONCLUSIONS:Within an ERAS pathway after cardiac surgery, low-dose ketamine infusion was associated with reduced opioid use and improved early postoperative pain control without increased central nervous system adverse events, supporting its role as a safe adjunct in postoperative analgesia.
PMID: 43026044
ISSN: 1532-8422
CID: 6075937

The Dolphin Sign on fetal heart rate tracing: maternal-fetal signal ambiguity during the second stage of labor

Vintzileos, Anthony; Chavez, Martin
PMID: 43003294
ISSN: 1097-6868
CID: 6075749

WGO AI Guidelines: Manuscript 3 AI on the Horizon-Part I Review on AI in Upper GI and Biliopancreatic Endoscopy

Saraiva, Miguel M; da Costa, António M M P; de Carvalho, Matheus F; Espino, Alberto; Sethi, Amrita; Zatarain, Ana; Metz, Andrew; Riquelme, Arnoldo; Kaffes, Arthur; Almuhaidb, Aymen; Agudo, Belén; González, Carlos A; Kim, Grace E; Vargas, Jose I; Kok, Khoon S; Lovat, Laurence; Sabbagh, Luis C; Lera, Marcos; González, Mariano; Villarroel, Mariano; Adams, Mason; Keegan, Mathew; Saxena, Payal; Gonda, Tamas; Siddiqui, Uzma D; Aggarwal, Vipul; Marlicz, Wojciech; Canavesi, Adrian; Silva, Adriana F; Pérez-Gonzalez, Ana; Velasquez, Andrea; Taullard, Andrés; Bercier, Baret; Dickson, Chance; Ejima, Gustavo; Fortes, Erika B; Filho, Hiram M N; González, Ivan; Mota, Joana; Sasso, João G R J; de Oliveira, Luiza B; Almeida, Maria J; Boghossian, Mateus B; Alrossais, Naif; Mingos, Nicholas; González, Nicolas; Cardoso, Pedro; de Moura, Eduardo G H; Widmer, Jessica; Macedo, Guilherme; ,
Artificial intelligence is increasingly transforming gastrointestinal endoscopy, particularly in endoscopic ultrasound (EUS), biliary disease, and upper gastrointestinal (GI) endoscopy. EUS plays a key role in evaluating subepithelial lesions (SELs) and solid and cystic pancreatic neoplasms, incorporating techniques such as elastography and contrast enhancement. Nonetheless, its diagnostic performance remains strongly operator-dependent, with notable interobserver variability and only moderate accuracy even among experienced endosonographers. Computational models applied to EUS images and videos have shown encouraging results in lesion detection, characterization, and risk stratification, in some cases reaching or exceeding expert-level performance. However, most available data are retrospective and derived from single-center studies. Cholangiocarcinoma continues to be associated with poor outcomes, largely due to delayed diagnosis and the difficulty of distinguishing malignant from benign biliary strictures. Although advances in cholangioscopy, imaging, and tissue acquisition have improved diagnostic yield, indeterminate strictures remain frequent. The incorporation of artificial intelligence into imaging analysis, radiologic assessment, and tissue evaluation may improve diagnostic precision, decrease unnecessary procedures, and provide real-time decision support. In upper GI endoscopy, detection and characterization of esophageal and gastric neoplasia remain inconsistent in daily practice and are highly dependent on operator expertise. Emerging systems can enhance lesion recognition, reduce variability among observers, and assist real-time assessment. Overall, these technologies represent a promising adjunct across endoscopic modalities, although prospective multicenter validation and real-time clinical integration are still required for widespread adoption.
PMID: 43000639
ISSN: 1539-2031
CID: 6075716

Arthroscopic Targeted Anchor Placement During Broström Repair: A Minimally Invasive Technique Guide

Halpern, Robert; Spadafora, Philip; Martin, Kevin D; Efremov, Kristian
Ankle sprains are among the most common orthopaedic injuries, with 20% to 30% of patients progressing to chronic lateral ankle instability despite conservative management. Arthroscopic lateral ankle ligament repair has shown outcomes comparable with open Broström repair while allowing treatment of concomitant intra-articular pathology. However, standard arthroscopic techniques may limit accurate anchor placement on the fibular footprint or require an accessory anterolateral portal, increasing incision burden, technical complexity, and risk to the superficial peroneal nerve. We describe an easily reproducible, arthroscopic targeted anchor placement technique for Broström repair using a 1.9-mm needlescope without the need for an accessory viewing portal. The procedure uses standard anteromedial and anterolateral portals, with the needlescope advanced directly to the anterior talofibular ligament fibular footprint for visualization. Knotless suture anchors are placed through the needlescope cannula, eliminating the need for an accessory anterolateral portal and the need for multiple assistants. This minimally invasive technique reduces incision burden while maintaining precise anchor placement. By avoiding an accessory lateral portal, it may decrease the risk of superficial peroneal nerve injury while preserving the benefits of arthroscopic lateral ankle ligament repair.
PMCID:13768953
PMID: 43034634
ISSN: 2212-6287
CID: 6075967

Arthroscopic Targeted Anchor Placement During Broström Repair: A Minimally Invasive Technique Guide

Halpern, Robert; Spadafora, Philip; Martin, Kevin D; Efremov, Kristian
Ankle sprains are among the most common orthopaedic injuries, with 20% to 30% of patients progressing to chronic lateral ankle instability despite conservative management. Arthroscopic lateral ankle ligament repair has shown outcomes comparable with open Broström repair while allowing treatment of concomitant intra-articular pathology. However, standard arthroscopic techniques may limit accurate anchor placement on the fibular footprint or require an accessory anterolateral portal, increasing incision burden, technical complexity, and risk to the superficial peroneal nerve. We describe an easily reproducible, arthroscopic targeted anchor placement technique for Broström repair using a 1.9-mm needlescope without the need for an accessory viewing portal. The procedure uses standard anteromedial and anterolateral portals, with the needlescope advanced directly to the anterior talofibular ligament fibular footprint for visualization. Knotless suture anchors are placed through the needlescope cannula, eliminating the need for an accessory anterolateral portal and the need for multiple assistants. This minimally invasive technique reduces incision burden while maintaining precise anchor placement. By avoiding an accessory lateral portal, it may decrease the risk of superficial peroneal nerve injury while preserving the benefits of arthroscopic lateral ankle ligament repair.
PMCID:13768953
PMID: 43034634
ISSN: 2212-6287
CID: 6075968

Safety and Efficacy of Low-Dose Ketamine Infusion for Pain Management after Cardiac Surgery:A Single Center Pre-Post Analysis

Hall, James; Yi, Hyogun; Weihs, Jenna; Rajan, Anand; Weinberger, Andrew; Sharma, Vivek; Yoo, Noah
OBJECTIVES/OBJECTIVE:To evaluate whether the addition of continuous low-dose ketamine infusion to an enhanced recovery after surgery (ERAS) protocol reduces postoperative opioid consumption and improves pain control after cardiac surgery. DESIGN/METHODS:Single-center, retrospective, before-and-after cohort study with propensity score matching. SETTING/METHODS:University-affiliated tertiary care hospital cardiothoracic intensive care unit. PARTICIPANTS/METHODS:Adult patients undergoing cardiac surgery and admitted postoperatively to the cardiothoracic intensive care unit between June 2023 and January 2025. INTERVENTIONS/METHODS:Patients managed under an ERAS protocol without ketamine (control) were compared with patients managed under ERAS plus a continuous postoperative low-dose ketamine infusion (0.1-0.3 mg/kg/h). MEASUREMENTS AND MAIN RESULTS/RESULTS:The primary outcome was opioid consumption in morphine milligram equivalents (MME) from postoperative day (POD) 0-2. Secondary outcomes included pain scores, time to first analgesic, recovery metrics, length of stay, and adverse events. Of 548 screened patients, 244 were included after propensity matching (122 ketamine, 122 control). Ketamine was associated with lower cumulative opioid use through POD2 (30 vs 52.5 MME; p = 0.003), with reductions on POD0 and POD1. Time to first analgesic was longer (7.4 vs 4.5 h; p < 0.001), and maximum pain scores were lower across the first 48 hours (all p < 0.05). Intensive care unit length of stay was modestly longer, while hospital length of stay was shorter in the ketamine group. No hallucinations were observed, delirium rates were low, and urinary retention was significantly reduced (9.8% vs 34%; p < 0.001). CONCLUSION/CONCLUSIONS:Within an ERAS pathway after cardiac surgery, low-dose ketamine infusion was associated with reduced opioid use and improved early postoperative pain control without increased central nervous system adverse events, supporting its role as a safe adjunct in postoperative analgesia.
PMID: 43026044
ISSN: 1532-8422
CID: 6075938